Literature DB >> 2791195

Circadian pharmacokinetics of methotrexate.

B A Robinson1, E J Begg, B M Colls, G M Jeffery, J R Sharman.   

Abstract

Six patients with intermediate- and high-grade non-Hodgkin's lymphoma were treated with 400 mg/m2 i.v. methotrexate (MTX) at 0600 and 1800 hours. Despite evidence of circadian rhythms in renal function, the pharmacokinetics of total and free serum MTX showed no significant difference between these two times. The marked two-fold circadian variation in MTX pharmacokinetics previously reported in rats was not observed in these patients.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2791195     DOI： 10.1007/bf00257452

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  17 in total

Review 1.  Clinical pharmacokinetics of methotrexate.

Authors:  D D Shen; D L Azarnoff
Journal:  Clin Pharmacokinet       Date:  1978 Jan-Feb       Impact factor: 6.447

2.  Effect of route of administration and effusions on methotrexate pharmacokinetics.

Authors:  S H Wan; D H Huffman; D L Azarnoff; R Stephens; B Hoogstraten
Journal:  Cancer Res       Date:  1974-12       Impact factor: 12.701

Review 3.  Chronopharmacology.

Authors:  V Marks; J English; W Aherne; J Arendt
Journal:  Clin Biochem       Date:  1985-06       Impact factor: 3.281

Review 4.  Quo vadis basic and clinical chronobiology: promise for health maintenance.

Authors:  F Halberg
Journal:  Am J Anat       Date:  1983-12

5.  Adrenal response to serial cosyntropin stimulation after repeated high-dose prednisone administration in patients with lymphoma.

Authors:  K Zamkoff; J Kirshner; D Cass; M Miller
Journal:  Cancer Treat Rep       Date:  1981 Jul-Aug

Review 6.  Circadian changes of drug disposition in man.

Authors:  A Reinberg; M H Smolensky
Journal:  Clin Pharmacokinet       Date:  1982 Sep-Oct       Impact factor: 6.447

7.  High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.

Authors:  R B Jones; J M Collins; C E Myers; A E Brooks; S M Hubbard; J E Balow; M F Brennan; R L Dedrick; V T DeVita
Journal:  Cancer Res       Date:  1981-01       Impact factor: 12.701

8.  The effect of abolition of the endogenous corticosteroid rhythm on the circadian variation in methotrexate toxicity in the rat.

Authors:  J English; G W Aherne; J Arendt; V Marks
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

9.  The effect of timing of a single injection on the toxicity of methotrexate in the rat.

Authors:  J English; G W Aherne; V Marks
Journal:  Cancer Chemother Pharmacol       Date:  1982       Impact factor: 3.333

10.  Methotrexate cerebrospinal fluid and serum concentrations after intermediate-dose methotrexate infusion.

Authors:  W E Evans; P R Hutson; C F Stewart; D A Cairnes; W P Bowman; G Rivera; W R Crom
Journal:  Clin Pharmacol Ther       Date:  1983-03       Impact factor: 6.875
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.